膵がん薬物療法は他のがん種とどう違う？・第23回がんチューブ専門医ダイレクトライブ

膵がん薬物療法は他のがん種とどう違う？・第23回がんチューブ専門医ダイレクトライブ

by がんチューブ (Japanese Cancer Therapy Society)

Life & Natural Systems Medicine & Health MJCLOncologyMJCL2Chemotherapy
🎙 がんチューブ (Japanese Cancer Therapy Society) 👥 5K 📅 February 8, 2026 ⏱ 122 min 👁 13K 📄 expert opinion 🧭 2026-08-16
Available in: English (current) Français

Keywords

pancreatic cancerFOLFIRINOXgemcitabinenab-paclitaxelKRAS inhibitor

Summary

This live-streamed medical lecture, part of the ‘Cancer Tube’ series by the Japanese Society of Medical Oncology, focuses on the unique challenges and recent advances in drug therapy for pancreatic cancer. The guest speaker, Dr. Makoto Ueno, a specialist from Kanagawa Cancer Center, delivers a keynote presentation explaining why pancreatic cancer is difficult to treat, highlighting the lack of effective early detection methods, the aggressive nature of the disease, and the physical decline (cachexia) and dense fibrous tissue that hinder drug delivery. He reviews the historical evolution of chemotherapy, from the era of gemcitabine monotherapy to the introduction of FOLFIRINOX and gemcitabine plus nab-paclitaxel in the 2010s, which improved survival. He also discusses the limited role of immunotherapy and the promising development of KRAS inhibitors, which target a mutation present in about 90% of pancreatic cancers. The video includes a discussion with a pancreatic cancer survivor, Mr. Shinichi Ida, who shares his personal treatment journey and asks patient-relevant questions. The second half features a Q&A session covering topics such as the role of BRCA mutations, the use of platinum-based agents, the timing of genetic testing, the management of pain, and the potential of heavy-ion therapy. The experts emphasize the importance of early genetic testing, particularly for BRCA, and the need for a multidisciplinary approach to manage complications like biliary obstruction.

220 words

Critical Evaluation

Value of the Information & Strength of the Argument

The video provides valuable, up-to-date information on pancreatic cancer drug therapy, with a strong emphasis on evidence-based medicine. The speaker, Dr. Ueno, is a recognized expert and presents data from key clinical trials, such as the JCOG 1611 study, which compared different first-line regimens. He clearly explains the rationale behind treatment choices and the challenges specific to pancreatic cancer, such as the dense stroma and cachexia. The argumentation is solid, with logical progression from historical context to current standards and future directions. The inclusion of a survivor’s perspective adds practical value, and the Q&A section addresses common patient concerns with expert responses. However, some statements are based on personal experience and may not be universally applicable, and the discussion is limited by the time constraints of a live format.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, as the content is based on peer-reviewed studies and clinical guidelines, though specific citations are not always provided in the video. The speaker references his own research group’s work (JCOG) and mentions recent publications, but does not give full citations. The title accurately reflects the content, which is a focused discussion on pancreatic cancer drug therapy. The video is produced by a reputable professional society, adding to its credibility. The presence of a sponsor is not mentioned, and the content appears to be unbiased. The Q&A format allows for clarification of complex topics, but the lack of formal references may limit the viewer’s ability to verify the information independently.

258 words

Title / Content Match

The title accurately reflects the content, which focuses on the differences in drug therapy for pancreatic cancer compared to other cancers, as presented by a specialist.

Quality & Reliability

8/10

The video features a board-certified oncologist (Dr. Makoto Ueno) specialized in pancreatic cancer, with a structured presentation and Q&A session. The information is evidence-based, referencing clinical trials (e.g., JCOG 1611) and current guidelines. However, it is primarily an expert opinion and discussion, not a peer-reviewed publication, and some statements are based on personal experience.

Chapters

Cited Sources

Concurring Sources

  • JCOG 1611 trial results — The speaker mentions this trial comparing GEM+nab-PTX and modified FOLFIRINOX, which was published in JCO in 2025.

Contribution & Novelties

The video provides a comprehensive overview of the current state of pancreatic cancer drug therapy, with a focus on the unique challenges compared to other cancers. It highlights the limited treatment options and the recent advances, such as the introduction of nanoliposomal irinotecan and the promising development of KRAS inhibitors. The discussion with a survivor adds a patient perspective that is often missing in medical lectures. The video also emphasizes the importance of early genetic testing, particularly for BRCA mutations, and the need for a multidisciplinary approach.

Pour aller plus loin :

  • KRAS inhibitors in cancer therapy — Overview of KRAS inhibitor development, relevant to the discussion of future pancreatic cancer treatments.
  • FOLFIRINOX regimen for pancreatic cancer — Original trial of FOLFIRINOX, a key treatment discussed in the video.
  • BRCA mutations and pancreatic cancer — Information on BRCA mutations and their role in pancreatic cancer, relevant to the discussion on genetic testing.

152 words

Radar Profile

The radar profile shows high scores in information quantity, quality, and reliability, with a slightly lower technical level, indicating that the content is accessible to a general audience while maintaining scientific depth. The overall balance suggests a well-rounded educational resource.

Reliability 8/10